- /
- Supported exchanges
- / US
- / ANGO.NASDAQ
AngioDynamics Inc (ANGO NASDAQ) stock market data APIs
AngioDynamics Inc Financial Data Overview
AngioDynamics, Inc., a medical technology company, designs, manufactures, and sells medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. It offers Auryon Atherectomy system that delivers an optimized wavelength and short pulse width to remove lesions while preserving vessel wall endothelium. The company's thrombus management portfolio includes AlphaVac mechanical thrombectomy system, an emergent mechanical aspiration device that eliminates the need for perfusionist support; thrombolytic catheters that are used to deliver thrombolytic agents, which are drugs to dissolve blood clots in hemodialysis access grafts, arteries, veins, and surgical bypass grafts; and AngioVac venous drainage cannula and extracorporeal circuit for use in extracorporeal circulatory support procedures for periods of up to six hours, as well as with other manufacturers' off-the-shelf pump, filter, and reinfusion cannula facilitate venous drainage. It also offers NanoKnife IRE Ablation System, an alternative to traditional thermal ablation for the surgical ablation of soft tissue; and peripheral products, which includes angiographic catheters, diagnostic and interventional guidewires, and coaxial micro-introducer kits for use in peripheral diagnostic and interventional procedures. In addition, the company provides abscession drainage catheters for multi-purpose/general, nephrostomy, and biliary drainage; micro-access kits offer interventional physicians a smaller introducer system for minimally invasive procedures; VenaCure EVLT system that are used in endovascular laser procedures to treat superficial venous disease; and Solero Microwave Tissue Ablation System includes solero microwave generator and the solero MW applicators. AngioDynamics, Inc. was founded in 1988 and is headquartered in Latham, New York.
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with AngioDynamics Inc (top by weight)
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get AngioDynamics Inc data using free add-ons & libraries
Get AngioDynamics Inc Fundamental Data
AngioDynamics Inc Fundamental data includes:
- Net Revenue: 301 M
- EBITDA: -1 614 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-10-02
- EPS/Forecast: -0.12
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
AngioDynamics Inc News
New
These 7 tech stocks have seen heavy insider selling even as prices are rising
- Getty Images/iStockphoto Is the stock market at a near-term top? Here’s a troubling new data point to consider: Corporate insiders — companies’ officers and directors — are more bearish tha...
H.C. Wainwright Reaffirms Buy Rating on AngioDynamics (ANGO) After Strong Q1 Performance
AngioDynamics, Inc. (NASDAQ:ANGO) is one of billionaire Steve Cohen’s small-cap stock picks with huge upside potential. On October 6, H.C. Wainwright reiterated its Buy rating on AngioDynamics (NASD...
AngioDynamics Eyes Growth Despite Tariffs
AngioDynamics, Inc. (NASDAQ:ANGO) posted stronger-than-expected first-quarter results across its Med-Tech businesses and lifted its fiscal 2026 guidance. Canaccord Genuity analysts, led by John Young...
ANGO Stock Gains Following Q1 Earnings Beat, Gross Margin Improves
AngioDynamics, Inc. ANGO reported a pro-forma adjusted loss per share of 10 cents for first-quarter fiscal 2026, marking an improvement from the year-ago quarter’s adjusted loss of 11 cents. The Zac...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.